Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors

Int J Gynecol Pathol. 2025 Jan 1;44(1):88-93. doi: 10.1097/PGP.0000000000001029. Epub 2024 May 29.

Abstract

Androgen receptor splicing variant 7 (AR-V7) is a truncated variant of the AR mRNA that may be a predictive biomarker for AR-targeted therapy. AR-V7 has been described in prostate, breast, salivary duct, and hepatocellular carcinomas as well as mammary and extra-mammary Paget disease. We report 2 gynecologic cancers occurring in the lower uterine segment and ovary and both harboring AR-V7 by targeted RNA sequencing. The uterine tumor was an undifferentiated carcinoma consisting of epithelioid cells and focally spindled cells arranged in sheets, nests, and cords associated with brisk mitotic activity and tumor necrosis. The ovarian tumor consisted of glands with cribriform and solid architecture and uniform cytologic atypia. ER and PR were positive in the ovarian tumor and negative in the uterine tumor. Both were positive for AR and negative for HER2, GATA3, and NKX3.1. DNA methylation profiling showed epigenetic similarity of the AR-V7-positive gynecologic cancers to AR-V7-positive breast cancers rather than to prostate cancers. AR-V7 may underpin rare gynecologic carcinomas with undifferentiated histology or cribriform growth reminiscent of prostatic adenocarcinoma and breast invasive ductal carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biomarkers, Tumor / genetics
  • DNA Methylation
  • Female
  • Genital Neoplasms, Female / genetics
  • Genital Neoplasms, Female / pathology
  • Humans
  • Middle Aged
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology
  • Receptors, Androgen* / genetics
  • Uterine Neoplasms / genetics
  • Uterine Neoplasms / pathology

Substances

  • Receptors, Androgen
  • AR protein, human
  • Biomarkers, Tumor